View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Deals Analysis
April 26, 2021

North America’s medical devices industry saw a rise of 10.11% in deal activity during March 2021

North America’s medical devices industry saw a rise of 10.11% in deal activity during March 2021, when compared with the last 12-month average, led by Hellman & Friedman’s $1bn acquisition of Cardinal Health, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.

 

A total of 98 medical devices industry deals worth $4.89bn were announced for the region in March 2021, against the 12-month average of 89 deals.

Of all the deal types, venture financing saw most activity in March 2021 with 64 transactions, representing a 65.3% share for the region.

In second place was M&A with 26 deals, followed by private equity deals with eight transactions, respectively capturing a 26.5% and 8.2% share of the overall deal activity for the month.

In terms of value of deals, M&A was the leading category in North America’s medical devices industry with $2.41bn, while venture financing and private equity deals totalled $1.3bn and $1.18bn, respectively.

North America medical devices industry deals in March 2021: Top deals

The top five medical devices deals accounted for 55.8% of the overall value during March 2021.

The combined value of the top five medical devices deals stood at $2.73bn, against the overall value of $4.89bn recorded for the month.

The top five medical devices industry deals of March 2021 tracked by GlobalData were:

1) Hellman & Friedman’s $1bn private equity deal with Cardinal Health

2) The $695m acquisition deal with Resolution Bioscience by Agilent Technologies

3) Agiliti’s $475m acquisition of Northfield Medical

4) The $320m acquisition of Asuragen by Bio Techne

5) Organon &’s acquisition of Alydia Health for $240m.

Related Companies

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU